Glenmark Pharmaceuticals has announced the launch of Vancomycin Hydrochloride for Injection USP in 500 mg/vial and 1 g/vial strengths in the United States market, further strengthening the company’s injectable medicines portfolio. The newly launched product is bioequivalent and therapeutically equivalent to the reference listed drug Vancomycin Hydrochloride for Injection USP marketed by Fresenius Kabi USA. The launch expands Glenmark’s offering of affordable injectable treatment options for healthcare providers and patients across the US.
According to IQVIA sales data for the 12-month period ending March 2026, the US market for Vancomycin Hydrochloride for Injection USP in the 500 mg/vial and 1 g/vial category recorded annual sales of approximately $37.9 million. Vancomycin Hydrochloride for Injection is widely used in healthcare settings for the treatment of serious bacterial infections where injectable antibiotic therapy is required. The introduction of the product aligns with Glenmark’s strategy of expanding access to quality and cost-effective generic medicines while strengthening its position in the US pharmaceutical market.
Marc Kikuchi, President and Business Head – North America at Glenmark Pharmaceuticals, said the launch reflects the company’s continued commitment to improving access to affordable and reliable medicines in the United States. He added that the introduction of the injectable product further strengthens Glenmark’s growing portfolio in the injectable therapeutics segment while supporting healthcare providers with dependable treatment solutions.
The launch also reinforces Glenmark’s focus on expanding its generics and specialty pharmaceutical business through product portfolio diversification and market expansion initiatives. Injectable medicines continue to represent an important growth area for pharmaceutical companies due to increasing demand for hospital-administered therapies and complex treatment solutions.
Glenmark Pharmaceuticals operates as a research-led global pharmaceutical company with a strong presence across branded formulations, generics, innovative medicines, and consumer healthcare products. The company has established operations in more than 80 countries and maintains a diversified portfolio focused on therapeutic areas including respiratory care, dermatology, and oncology.
The company currently operates 11 manufacturing facilities across four continents, supported by six research and development centres focused on innovation, formulation development, and advanced pharmaceutical technologies. Through its integrated global manufacturing and research infrastructure, Glenmark continues to expand its capabilities across oral solids, injectables, specialty medicines, and complex generics.
Glenmark has been increasing investments in regulated markets including North America while focusing on expanding its portfolio of high-quality and affordable pharmaceutical products. The company stated that its long-term strategy remains centered on combining innovation with accessibility to address evolving healthcare needs worldwide.
The launch of Vancomycin Hydrochloride for Injection USP also reflects growing industry demand for reliable generic injectable products that support healthcare systems in managing treatment accessibility and cost efficiency. Hospital and institutional healthcare providers increasingly rely on high-quality generic injectable therapies to support essential treatment requirements across a broad range of medical conditions.
Glenmark continues to strengthen its North American business through new product launches, portfolio expansion, and strategic investments in manufacturing and regulatory capabilities. The company believes its expanding injectable portfolio will support future growth opportunities in the US pharmaceutical market while reinforcing its commitment to delivering accessible and affordable healthcare solutions.
